AA
BMRN icon

Apriem Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Apriem Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-275
Closed -$38K – 520
2015
Q2 		$38K Buy
+275
New +$34.1K 0.01% 241

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Apriem Advisors's BMRN Position: Q3 2015 in Review

Apriem Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2015, closing a stake of 275 shares — an estimated $38K sold.

Apriem Advisors first reported a position in BMRN in Q2 2015 and held it in 1 quarter. The position peaked at $38K in Q2 2015. 393 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

  • Apriem Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Apriem Advisors sold 275 BioMarin Pharmaceuticals shares in Q3 2015, an estimated $38K.
  • Apriem Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Apriem Advisors's BioMarin Pharmaceuticals position peaked at $38K in Q2 2015.
  • 393 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on Apriem Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.